Here's How to Play AbbVie Stock as it Reaches Golden Cross

Core Insights - AbbVie's stock has achieved a "golden cross," indicating bullish momentum and potential for prolonged upward trends [1][9] - The company has successfully launched new drugs, Skyrizi and Rinvoq, to offset the decline in sales from Humira due to patent loss [4][5] - AbbVie expects significant revenue growth driven by these new products and a strong pipeline [25][26] Group 1: Stock Performance - AbbVie's stock has been trading above its 50-day and 200-day simple moving averages since early July, signaling positive momentum [1] - The stock has gained 9.8% year-to-date, outperforming the industry and the S&P 500 index [16][18] Group 2: Product Performance - Skyrizi and Rinvoq generated combined sales of $5.1 billion in Q1 2025, reflecting over 65% growth year-over-year [6][9] - AbbVie anticipates combined sales of Skyrizi and Rinvoq to reach approximately $24.7 billion in 2025 and over $31 billion by 2027 [7] Group 3: Pipeline and Acquisitions - AbbVie has a diverse pipeline with several early/mid-stage candidates, including promising therapies for blood cancers and solid tumors [10][11] - The company has been active in acquisitions, including the recent purchase of Capstan Therapeutics for nearly $2.1 billion, enhancing its immunology pipeline [12][13] Group 4: Challenges and Market Conditions - Humira's sales have declined by almost 50% in Q1 2025 due to biosimilar competition [14] - Sales of Juvederm fillers have also decreased by 10.2% in Q1 2025, impacted by challenging market conditions in the U.S. and China [15] Group 5: Future Outlook - AbbVie expects to return to robust mid-single-digit revenue growth in 2025, driven by the performance of Skyrizi and Rinvoq [25] - The company is well-positioned for continued strong growth, with no significant loss of exclusivity events anticipated for the rest of the decade [25][26]